Las Vegas Sun

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...
Wall Street Journal

The ‘Class of AI’ Enters the Workforce

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Ryan Knutson: A funny thing has been happening at college graduations this spring ...
Science Daily

Human organoids reveal how to reverse “irreversible” nerve damage

Cambridge researchers created miniature brain-and-spinal-cord systems in the lab that can send signals and even trigger tiny ...
Science Daily

1.5-million-year-old fossil face is forcing a rethink of human origins

Scientists have digitally reconstructed the face of a 1.5-million-year-old Homo erectus fossil from Ethiopia, uncovering an unexpectedly primitive appearance. While its braincase fits with classic ...

Johnson & Johnson: RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small ...

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...